Summit Therapeutics Inc.
SMMT
$18.22
-$0.69-3.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 493.55M | 411.09M | 64.49M | 60.42M | 57.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -205.00K | -205.00K | -205.00K | -205.00K | -179.00K |
| Total Operating Expenses | 935.11M | 759.28M | 235.45M | 210.99M | 181.59M |
| Operating Income | -935.11M | -759.28M | -235.45M | -210.99M | -181.59M |
| Income Before Tax | -921.62M | -746.08M | -240.76M | -221.32M | -196.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -921.62 | -746.08 | -240.76 | -221.32 | -196.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -921.62M | -746.08M | -240.76M | -221.32M | -196.68M |
| EBIT | -935.11M | -759.28M | -235.45M | -210.99M | -181.59M |
| EBITDA | -934.99M | -759.18M | -235.37M | -210.90M | -181.49M |
| EPS Basic | -1.24 | -1.01 | -0.33 | -0.31 | -0.28 |
| Normalized Basic EPS | -0.78 | -0.63 | -0.19 | -0.18 | -0.16 |
| EPS Diluted | -1.25 | -1.02 | -0.35 | -0.32 | -0.28 |
| Normalized Diluted EPS | -0.78 | -0.63 | -0.19 | -0.18 | -0.16 |
| Average Basic Shares Outstanding | 2.96B | 2.94B | 2.91B | 2.87B | 2.84B |
| Average Diluted Shares Outstanding | 2.96B | 2.94B | 2.91B | 2.87B | 2.84B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |